| Objective:IL-10 is critically involved in tumorigenesis. We investigated the association between interleukin-10 (IL-10)-1082/-819/-592 promoter polymorphism, plasma IL-10 levels and risk of laryngeal squamous cell carcinoma (LSCC). Researched the inhibition function of IL-10 on NF-κB and activation function on Jak-Stat3 in Hep-2 cells. Methods:In a prospective, case-control study 146 patients with LSCC,61 patients with vocal leukoplakia and 119 healthy controls were genotyped for the IL-10 gene (IL-10 -1082 G/A,-819 C/T and -592 C/A) using pyro sequencing and plasma IL-10 levels were analyzed by ELISA. Using the Western Blot to detect effects of IL-10 on the NF-κB, Jak-Stat3 protein in laryngeal carcinoma Hep-2 cells. Results:Patients with LSCC had a significantly higher frequency of AC at -592 and-819 (OR=1.82, P=0.024) than controls and higher AG at -1082(OR= 2.20, P=0.037). Patients with advanced laryngeal carcinoma had a significantly higher frequency of AG+GG at -1082 than those with initial laryngeal carcinoma (OR =3.13, P=0.008 vs. OR=2.06, P=0.068). Patients with lymph node metastasis had a significantly higher frequency of AG+GG at-1082 than those with no lymph node metastasis (OR=2.97, P=0.048 vs. OR=2.23 P=0.035). Moreover patients with high frequencies of genotype polymorphism had high plasma IL-10 concentrations. IL-10 has an inhibitory effect on NF-κB and active effect on the Jak-Stat3 protein in Hep-2 cells. Conclusions:This study suggests that the IL-10 -1082/-819/-592 promoter polymorphism and corresponding high plasma IL-10 concentrations are associated with laryngeal carcinoma in Chinese Han patients, and that differences in genotype distribution and plasma IL-10 concentrations may be associated with the stage and lymph node metastasis status of LSCC and IL-10 may inhibit NF-κB and activate Jak-Stat3 pathway to promote laryngeal carcinoma development. |
PDF Full Text Request